Robin Thomma
PhD student
My background
I studied a bachelor in health sciences and a master in medicine and clinical research at Maastricht University. Following my studies, I worked as a resident in neurology (not in training) for one year at the Albert Schweitzer hospital in Dordrecht.
In 2021 I started my PhD trajectory at the departments of neurology and immunology of the Erasmus MC.
My main research interests revolve around translational research on the crossroads of these disciplines.
My projects
The general focus of my projects is on biomarkers in GBS.
In these projects, we aim to describe the (longitudinal) occurrence of promising biomarkers in relation to the clinical phenotype of patients with GBS. Markers that I work with include anti-ganglioside antibodies, soluble interleukin-2 receptor, neurofilament light chain, preceding infection serology, and single nucleotide polymorphisms (in genome-wide association studies).
With the results of these projects, we hope to improve care and treatment for patients with GBS through aiming to improve diagnostics, prognostics, and treatment strategies for these patients.
A list of research articles
-
Nfl prognostic model
-
Study on GBS
In this study, we aim to explore whether addition of the biomarker neurofilament light chain, a blood marker for nerve damage, to the existing mEGRIS and mEGOS prediction tools could further improve the performance of these tools. This study is performed using clinical data and blood samples from patients included in the second intravenous immunoglobulin […]
-
-
Anti-ganglioside antibodies in patients with GBS
-
Study on GBS
In this study, we aim to determine the presence of anti-ganglioside antibodies in patients with GBS and explore whether these are related to symptoms and prognosis. This study is performed using clinical data and blood samples from patients included in the International GBS Outcome Study (IGOS).
-
-
Genome Wide association study in patients with GBS
-
Study on GBS
In this study, we aim to investigate whether genetics (single nucleotide polymorphisms) could play a role in a patient’s susceptibility to develop GBS. This study is performed using clinical data and blood samples from patients included in the International GBS Outcome Study (IGOS) and several previous Dutch treatment trials.
-
